Precision Medicine in Oncology®

Eunice Wang, MD, provides an overview of currently available AML treatments and highlights the importance of mutational sequencing strategies.

China’s NMPA has accepted an sNDA for review, seeking the approval of repotrectinib for advanced solid tumors harboring NTRK fusions.

The top 5 OncLive videos of the week cover insights in multiple myeloma, AL amyloidosis, myelofibrosis, breast cancer, and sarcoma.

A new drug application for zurletrectinib has been accepted in China for the treatment of patients with NTRK gene fusion–positive advanced solid tumors.

The top 5 OncLive videos of the week cover insights in myelofibrosis, chronic lymphocytic leukemia, colorectal cancer, breast cancer, and ovarian cancer.

Nivolumab/ipilimumab is approved for dMMR/MSI-H mCRC and unresectable or metastatic HCC, larotrectinib wins full approval in NTRK+ solid tumors, and more.

Ashish Saxena, MD, PhD, discusses the evolving utility of targeted therapies for ALK-positive non–small cell lung cancer.

Suzanne Mahon DNS, RN, AOCN, AGN-BC, FAAN, discusses the importance of integrating genomic science into oncology practice.

Rachel N. Grisham, MD, discusses efficacy and tolerability data from the phase 2 ENGOT-OV60/GOG-3052/RAMP 201 subgroup analysis.

The FDA has granted full approval to larotrectinib for select patients with solid tumors harboring a NTRK gene fusion.

Daraxonrasib was safe and active in the pretreated advanced non–small cell lung cancer harboring RAS mutations.

Ecaterina Dumbrava, MD, discusses the rationale and clinical development of rezatapopt in ovarian cancer and other solid tumors harboring TP53 Y220C mutations.

The FDA has received an NDA for ziftomenib in relapsed/refractory NMP1-mutant acute myeloid leukemia.

Savolitinib plus osimertinib produced responses in pretreated MET-amplified or -overexpressed advanced non–small cell lung cancer harboring EGFR mutations.

Tanios S. Bekaii-Saab, MD, details studies of ctDNA-guided strategies that are elucidating the role of adjuvant therapies in CRC and agents of promise.

Here is your Q2 2025 preview spotlighting 7 FDA decisions to watch, including upcoming PDUFAs for nivolumab/ipilimumab, belzutifan, UGN-102, avutometinib/defactinib, and more.

Scott Kopetz, MD, PhD, FACP, discusses the safety of encorafenib plus cetuximab with/without chemotherapy in BRAF V600E–mutant metastatic colorectal cancer.

The top 5 OncLive videos of the week cover insights in multiple myeloma, HER2+ breast cancer, non¬–muscle-invasive bladder cancer, and ovarian cancer.

Fulzerasib plus cetuximab elicited deep efficacy in patients with KRAS G12C–mutated NSCLC enrolled in the phase 2 KROCUS study.

Adagrasib plus pembrolizumab continued to show promising efficacy in patients with KRAS G12C–mutated NSCLC and PD-L1 TPS of 50% or higher.

Pediatric patients with TRK fusion–positive sarcomas may be able to safely discontinue larotrectinib and resume treatment if needed without sacrificing response.

The investigational new drug application for the RDC SKB107 for the management of solid tumor bone metastases has been approved in China.

Pembrolizumab combination gets full approval in select HER2+ gastric/GEJ cancer, PSMA PET imaging agent is cleared for prostate cancer, and more from OncLive.

Aditya Shreenivas, MD, MS, discusses the association between Claudin 18 and MUC1 biomarkers and ongoing targeted therapy challenges.

Ajay Goel, PhD, AGAF, discusses the potential utility of CA19-9 with an exosome-based liquid biopsy as a diagnostic biomarker in early-stage pancreatic cancer.